ALVAC/Bivalent gp120/MF59 HIV Vaccine

ALVAC-based HIV vaccine with bivalent gp120 and MF59 adjuvant · Sanofi Pasteur and Novartis

Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for ALVAC/Bivalent gp120/MF59 HIV Vaccine, covering 2023-02-08 to 2023-02-08. Get the full timeline:

Most recent: Clinical Trial Update: Pivotal Phase 2b/3 ALVAC/Bivalent gp120/MF59 HIV Vaccine Prevention Safety and Efficacy Study in South Africa [Phase 2, Phase 3]

See pricing